ArticleBiomarkers in medicine2013
Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder.
Article in Biomarkers in medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02120729 (Pharmacogenetic Decision Support IT System for Psychiatric Hospitalization), which is not on this map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacogenetic Decision Support IT System for Psychiatric Hospitalization: RCT
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Pharmacokinetic Markers of Clinical Outcomes in Severe Mental Illness: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19.Translational psychiatry · 2021Pooled it
- Dietary caffeine to assess CYP1A2 activity, tailor clozapine doses, and predict treatment response: genetic, epigenetic and clinical analyses.Molecular psychiatry · 2026Article
- Rates of Divergent Pharmacogenes in a Psychiatric Cohort of Inpatients with Depression-Arguments for Preemptive Testing.Journal of xenobiotics · 2022Article
- Sub-Analysis of CYP-GUIDES Data: Assessing the Prevalence and Impact of Drug-Gene Interactions in an Ethnically Diverse Cohort of Depressed Individuals.Frontiers in pharmacology · 2022Article
- Unmanaged Pharmacogenomic and Drug Interaction Risk Associations with Hospital Length of Stay among Medicare Advantage Members with COVID-19: A Retrospective Cohort Study.Journal of personalized medicine · 2021Article
- Article
- The Future of Personalized Medicine in Space: From Observations to Countermeasures.Frontiers in bioengineering and biotechnology · 2021Review
- Clinical database of the CYP-guides trial: An open data resource on psychiatric hospitalization for severe depression.Data in brief · 2020Article
- No Effect of Dose Adjustment to theFrontiers in psychiatry · 2018Article
- Increased risk of hospitalization for ultrarapid metabolizers of cytochrome P450 2D6.Pharmacogenomics and personalized medicine · 2017Article
- Pharmacogenomics: A focus on antidepressants and atypical antipsychotics.The mental health clinician · 2016Article
- Article
- Combinatorial Versus Individual Gene Pharmacogenomic Testing in Mental Health: A Perspective on Context and Implications on Clinical Utility.The Yale journal of biology and medicine · 2015Review
- The clinical validity and utility of combinatorial pharmacogenomics: Enhancing patient outcomes.Applied & translational genomics · 2015Article
- A Naturalistic Study of the Effectiveness of Pharmacogenetic Testing to Guide Treatment in Psychiatric Patients With Mood and Anxiety Disorders.The primary care companion for CNS disorders · 2015Article
- The potential utility of pharmacogenetic testing in psychiatry.Psychiatry journal · 2014Review
- CYP2D6's functional status associated with the length of hospitalization stay in psychiatric patients: a twist in the tale or evidence that matters?Biomarkers in medicine · 2013Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
aimThis study aimed to determine the effect of the CYP2D6 genotype on the length of hospitalization stay for patients treated for major depressive disorder.
methodsA total of 149 inpatients with a diagnosis of major depressive disorder at the Institute of Living, Hartford Hospital (CT, USA), were genotyped to detect altered alleles in the CYP2D6 gene. Prospectively defined drug metabolism indices (metabolic reserve, metabolic alteration and allele alteration) were determined quantitatively and assessed for their relationship to length of hospitalization stay.
resultsHospital stay was significantly longer in deficient CYP2D6 metabolizers (metabolic reserve <2) compared with functional or suprafunctional metabolizers (metabolic reserve ≥2; 7.8 vs 5.7 days, respectively; p = 0.002).
conclusionCYP2D6 enzymatic functional status significantly affected length of hospital stay, perhaps due to reduced efficacy or increased side effects of the medications metabolized by the CYP2D6 isoenzyme. Functional scoring of CYP2D6 alleles may have a substantial impact on the quality of care, patient satisfaction and the economics of psychiatric treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.